106 related articles for article (PubMed ID: 23270928)
21. Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145.
Roomi MW; Kalinovsky T; Rath M; Niedzwiecki A
Oncol Rep; 2011 Dec; 26(6):1407-13. PubMed ID: 21874261
[TBL] [Abstract][Full Text] [Related]
22. Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.
Kindzelskii AL; Amhad I; Keller D; Zhou MJ; Haugland RP; Garni-Wagner BA; Gyetko MR; Todd RF; Petty HR
Histochem Cell Biol; 2004 Apr; 121(4):299-310. PubMed ID: 15042374
[TBL] [Abstract][Full Text] [Related]
23. Multifunctional Theranostic Liposomes Loaded with a Hypoxia-Activated Prodrug for Cascade-Activated Tumor Selective Combination Therapy.
Dai Y; Wang B; Sun Z; Cheng J; Zhao H; Wu K; Sun P; Shen Q; Li M; Fan Q
ACS Appl Mater Interfaces; 2019 Oct; 11(43):39410-39423. PubMed ID: 31578854
[TBL] [Abstract][Full Text] [Related]
24. Targeted Chemo-Photodynamic Combination Platform Based on the DOX Prodrug Nanoparticles for Enhanced Cancer Therapy.
Zhang Y; Huang F; Ren C; Yang L; Liu J; Cheng Z; Chu L; Liu J
ACS Appl Mater Interfaces; 2017 Apr; 9(15):13016-13028. PubMed ID: 28378992
[TBL] [Abstract][Full Text] [Related]
25. Photosensitizers in prostate cancer therapy.
Gheewala T; Skwor T; Munirathinam G
Oncotarget; 2017 May; 8(18):30524-30538. PubMed ID: 28430624
[TBL] [Abstract][Full Text] [Related]
26. NIR-Light-Activated Combination Therapy with a Precise Ratio of Photosensitizer and Prodrug Using a Host-Guest Strategy.
Chen H; Zeng X; Tham HP; Phua SZF; Cheng W; Zeng W; Shi H; Mei L; Zhao Y
Angew Chem Int Ed Engl; 2019 Jun; 58(23):7641-7646. PubMed ID: 30980463
[TBL] [Abstract][Full Text] [Related]
27. The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.
Nalbandian A; Djakiew D
Clin Exp Metastasis; 2006; 23(2):107-16. PubMed ID: 16912916
[TBL] [Abstract][Full Text] [Related]
28. Assembly of polymer micelles through the sol-gel transition for effective cancer therapy.
Khaliq NU; Oh KS; Sandra FC; Joo Y; Lee J; Byun Y; Kim IS; Kwon IC; Seo JH; Kim SY; Yuk SH
J Control Release; 2017 Jun; 255():258-269. PubMed ID: 28456679
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
30. Prodrug-embedded angiogenic vessel-targeting nanoparticle: A positive feedback amplifier in hypoxia-induced chemo-photo therapy.
Guo D; Xu S; Wang N; Jiang H; Huang Y; Jin X; Xue B; Zhang C; Zhu X
Biomaterials; 2017 Nov; 144():188-198. PubMed ID: 28837960
[TBL] [Abstract][Full Text] [Related]
31. Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
Tokay E; Güngör T; Hacıoğlu N; Önder FC; Gülhan ÜG; Tok TT; Çelik A; Ay M; Köçkar F
Eur J Med Chem; 2020 Feb; 187():111937. PubMed ID: 31841727
[TBL] [Abstract][Full Text] [Related]
32. Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
Shi C; Zhang N; Feng Y; Cao J; Chen X; Liu B
Cell Physiol Biochem; 2017; 41(4):1313-1324. PubMed ID: 28278500
[TBL] [Abstract][Full Text] [Related]
33. Porphyrin-grafted Lipid Microbubbles for the Enhanced Efficacy of Photodynamic Therapy in Prostate Cancer through Ultrasound-controlled
You Y; Liang X; Yin T; Chen M; Qiu C; Gao C; Wang X; Mao Y; Qu E; Dai Z; Zheng R
Theranostics; 2018; 8(6):1665-1677. PubMed ID: 29556348
[TBL] [Abstract][Full Text] [Related]
34. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor.
Nkepang G; Bio M; Rajaputra P; Awuah SG; You Y
Bioconjug Chem; 2014 Dec; 25(12):2175-88. PubMed ID: 25351441
[TBL] [Abstract][Full Text] [Related]
35. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
36. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
37. Phthalocyanine 4 (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts.
Colussi VC; Feyes DK; Mulvihill JW; Li YS; Kenney ME; Elmets CA; Oleinick NL; Mukhtar H
Photochem Photobiol; 1999 Feb; 69(2):236-41. PubMed ID: 10048316
[TBL] [Abstract][Full Text] [Related]
38. Design and Proof of Programmed 5-Aminolevulinic Acid Prodrug Nanocarriers for Targeted Photodynamic Cancer Therapy.
Wu J; Han H; Jin Q; Li Z; Li H; Ji J
ACS Appl Mater Interfaces; 2017 May; 9(17):14596-14605. PubMed ID: 28397487
[TBL] [Abstract][Full Text] [Related]
39. Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard.
Chakravarty PK; Carl PL; Weber MJ; Katzenellenbogen JA
J Med Chem; 1983 May; 26(5):633-8. PubMed ID: 6221099
[TBL] [Abstract][Full Text] [Related]
40. Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells.
Nishimura K; Matsumiya K; Miura H; Tsujimura A; Nonomura N; Matsumoto K; Nakamura T; Okuyama A
Int J Androl; 2003 Jun; 26(3):175-9. PubMed ID: 12755996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
